title: EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy.
abstract: Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).
authors.affiliation: Department of Chemical Engineering, National Tsing Hua University, 101, Section 2, Kuang-Fu Road, Hsin-chu 30013, Taiwan, ROC.
authors.forename: Hung-Wei
authors.initials: HW
authors.lastname: Yang
authors.forename: Yu-Jen
authors.initials: YJ
authors.lastname: Lu
authors.forename: Kun-Ju
authors.initials: KJ
authors.lastname: Lin
authors.forename: Sheng-Chieh
authors.initials: SC
authors.lastname: Hsu
authors.forename: Chiung-Yin
authors.initials: CY
authors.lastname: Huang
authors.forename: Shu-Han
authors.initials: SH
authors.lastname: She
authors.forename: Hao-Li
authors.initials: HL
authors.lastname: Liu
authors.forename: Chih-Wen
authors.initials: CW
authors.lastname: Lin
authors.forename: Min-Cong
authors.initials: MC
authors.lastname: Xiao
authors.forename: Shiaw-Pyng
authors.initials: SP
authors.lastname: Wey
authors.forename: Pin-Yuan
authors.initials: PY
authors.lastname: Chen
authors.forename: Tzu-Chen
authors.initials: TC
authors.lastname: Yen
authors.forename: Kuo-Chen
authors.initials: KC
authors.lastname: Wei
authors.forename: Chen-Chi M
authors.initials: CC
authors.lastname: Ma
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D055910:Antibodies, Immobilized / Q000737:chemistry / Q000276:immunology*; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D015251:Epirubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000276:immunology*; D005910:Glioma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006108:Graphite / Q000737:chemistry*; D006801:Humans; D051379:Mice; D049329:Nanostructures / Q000737:chemistry; D010087:Oxides / Q000737:chemistry; D010789:Phototherapy; D011092:Polyethylene Glycols / Q000737:chemistry
chemical_list: D000903:Antibiotics, Antineoplastic; D055910:Antibodies, Immobilized; D004337:Drug Carriers; D010087:Oxides; D011092:Polyethylene Glycols; D015251:Epirubicin; D006108:Graphite; D066246:ErbB Receptors